Delta Medical’s CIS Operations Director Sergey Piont met with Angela Putylina, Regional Director at Gilead Sciences, to review progress and align on future plans for collaboration in the CIS region.
Strategic Dialogue
During the working session, Delta Medical and Gilead Sciences — a global biopharmaceutical leader — discussed current performance across CIS markets, mid-term priorities, and shared objectives to ensure responsible access to high-quality therapies.
Focus Areas
The discussion emphasized:
- Strengthening compliance and supply reliability
- Supporting medical education initiatives
- Advancing Gilead’s innovative portfolio, including antiviral medicines for HIV and hepatitis C
- Exploring opportunities in oncology and cell therapy, tailored to regional healthcare needs
Leadership Perspective
“Partnership discipline and predictable execution are central to our model,” said Sergey Piont, Operations Director, CIS.
“We appreciate Gilead’s trust and the constructive dialogue that helps us plan for the next phase.”
Commitment to Progress
Delta Medical reaffirmed its dedication to building sustainable partnerships and improving healthcare outcomes in every country of its presence. The company values the relationship with Gilead Sciences and remains committed to advancing standards of care across the region.
